Drug

Omecamtiv mecarbil

In clinical development

ClassCardiac myosin activatorEmerging researchLate-stage development

RxNorm1036427 ChEMBLCHEMBL1800955 ATCC01CX10UNII2M19539ERK

Research papers

Active clinical trials

Protein targets

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial to Assess Efficacy and Safety of Omecamtiv Mecarbil in Patients With Symptomatic Heart Failure With Severely Reduced Ejection Fraction (COMET-HF)

Clinical trial2026-07-07Results expected Q3 2027 · ClinicalTrials.gov

Single-dose and Randomized, Single-center, Placebo- and Active-controlled, Crossover Study to Assess the Effect of Omecamtiv Mecarbil (OM) on QT/QTc Intervals in Healthy Subjects

Clinical trial2025-03-30Results posted · ClinicalTrials.gov

A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure With Reduced Ejection Fraction and Decreased Exercise Tolerance

Clinical trial2023-03-07Results posted · ClinicalTrials.gov

A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction (GALACTIC-HF)

Clinical trial2021-11-05Results posted · ClinicalTrials.gov

A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Omecamtiv Mecarbil in Japanese Subjects With Heart Failure With Reduced Ejection Fraction

Clinical trial2021-07-27Results posted · ClinicalTrials.gov

A Phase 1, Single Center Double-blind, Randomized, Placebo-controlled Study to Evaluate the Pharmacokinetics and Safety of Omecamtiv Mecarbil in Healthy Japanese Subjects

Clinical trial2021-07-27Results posted · ClinicalTrials.gov

Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure.

Research2020-11-13The New England journal of medicine

A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure

Clinical trial2013-09-01Completed · ClinicalTrials.gov

An Open Label, Multiple Dose Study to Investigate the Pharmacokinetics of Omecamtiv Mecarbil Administered Orally to Patients With Stable Heart Failure

Clinical trial2011-05-01Withdrawn · ClinicalTrials.gov

A First-in-Man, Phase I, Double-Blind, Randomized, Four-Way Crossover, Placebo-Controlled, Dose-Escalation, Pharmacokinetic and Pharmacodynamic Study of CK-1827452 (Omecamtiv Mecarbil) in Healthy Volunteers

Clinical trial2006-04-01Completed · ClinicalTrials.gov

Omecamtiv Mecarbil Post-trial Access Protocol for Subjects Completing Study 20110203 GALACTIC-HF

Clinical trial2026-11-27Withdrawn · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Omecamtiv mecarbil

RxNorm CUI

1036427

ChEMBL ID

CHEMBL1800955

ATC codes

C01CX10

UNII

2M19539ERK

Primary mechanism

Cardiac myosin activator

Pharmacology & targets

7 targets

Known molecular targets and mechanisms supported by curated pharmacology databases.

Myosin-7

MYH7 · P12883